Summary
Pancreatic cancer is a malignant tumor within the pancreatic
gland. Each year about 33,000 individuals in the United States are
diagnosed with this condition, and more than 60,000 in Europe.
Because early diagnosis of pancreatic cancer is difficult, the
prognosis is generally regarded as poor, with few victims still alive
five years after diagnosis, and complete remission extremely rare.
Researchers at the University of Nebraska medical center have
developed technologies for early diagnosis of pancreatic cancer
and inhibition of pancreatic cancer growth and metastasis. A novel
diagnostic technology, based on the highly specific detection of
MUC4 protein has been shown to be very accurate in distinguishing
pancreatic cancer from pancreatitis and other non-malignant
conditions. Further, researchers have discovered that inhibition of
MUC4 protein expression is directly associated with inhibition of
growth and metastasis of pancreatic cancer cells. Based on this
discovery, UNMC researchers have developed new treatment
modalities for pancreatic cancer that have been shown to be highly
effective in all stages of pancreatic cancer.

Market Value
Due to relative simplicity, the technology can be used as a direct
diagnosis tool as well as a routine scheduled pancreatic cancer
preventative examination tool. The technology is very precise and
effective inhibition of pancreatic cancer growth and metastasis with
a minimal systemic and/or local toxicity.

Features and Benefits
• Diagnosis of pancreatic cancer in its earliest developmental
stage
• Highly selective and effective inhibition of pancreatic cancer
growth and metastasis
• Minimal systemic and local toxicity
• Efficient diagnostic and therapeutical tool

Patent Issued
(TID - 64)

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with the University of Nebraska Medical Center.